Molecular Imaging Probe Development

摘要： 分子成像对肿瘤学的影响包括临床治疗的方方面面，包括早期 检测，指导临床前靶向治疗和生物标记物的开发，协助临床分期 疾病和监测对治疗的反应。分子成像的使用率可以显著降低 通过允许准确的患者治疗分层来开发新疗法所产生的成本 并允许对体内治疗的生物反应进行非侵入性的系列评估。然而，a 分子显像剂的开发和翻译已经出现了重大瓶颈， 特别是用于正电子发射断层扫描(PET探头)的那些。当前对快速技术的限制 PET靶向分子显像剂的开发和翻译包括但不限于； 靶向配基识别和显像剂的复杂设计、合成和筛选方法 发展。 因此，对具有广泛研究能力的杰出实验室科学家的需求显然越来越大。 在生物成像研究领域的经验，更具体地说在Hausner博士放射化学和 分子成像PET探头的探头优化。像豪斯纳博士这样的科学家提供了连续性， 对于学生和受训人员来说，稳定性和详细的科学知识远远超出了技术人员的能力，是至关重要的 以支持分子成像研究事业。这笔资金是表彰DR的绝佳机会。 豪斯纳的贡献，不仅是对萨克利夫实验室，也是对分子成像研究。它还将 允许他制定一条更明确、更稳定的职业道路，从事基础、翻译和 在萨克利夫研究计划内进行的临床分子成像研究，没有成为 独立调查员。豪斯纳博士将继续支持靶向分子成像的发展 萨克利夫实验室的癌症检测试剂，更具体地说，专注于改善 多肽类分子显像剂的药代动力学。正在开发中的分子显像剂 萨克利夫实验室支持分子研究中心的小鼠和非人类灵长类动物的临床前研究 和基因组成像，以及通过加州大学戴维斯综合癌症中心和 放射科。萨克利夫博士是首席支持股主任，他将继续与DR 豪斯纳计划、指导和监督拟议的研究。

ABSTRACT: The impact of Molecular Imaging on oncology encompasses all aspects of clinical management including early detection, guiding the preclinical development of targeted therapeutics and biomarkers, assisting staging of disease and monitoring response to therapeutics. Utilization of Molecular Imaging can significantly decrease the costs incurred with the development of new therapies by allowing accurate patient treatment stratification and allowing the non-invasive serial assessment of the biological response to treatment in vivo. However, a significant bottleneck has emerged for the development and translation of molecular imaging agents, specifically those utilized for positron emission tomography (PET probes). Current limitations for the rapid development and translation of targeted molecular imaging agents for PET include but are not limited to; the complex design, synthesis and screening approaches for both targeted ligand identification and imaging agent development. As such there is clearly a growing need for exceptional laboratory-based scientists with extensive research experience in the field of bioimaging research, more specifically in the case of Dr Hausner radiochemistry and probe optimization for molecular imaging PET probes. Scientists such as Dr Hausner provide the continuity, stability and detailed scientific knowledge to students and trainees far beyond that of a technician and are vital to sustain the molecular imaging research enterprise. This funding is an excellent opportunity to recognize Dr Hausner’s contributions, not only to the Sutcliffe laboratory but also to molecular imaging research. It will also allow him to develop a more defined and stable career path to pursue research in basic, translational, and clinical molecular imaging research within the Sutcliffe research program without the pressure of becoming an independent investigator. Dr Hausner will continue to support the development of targeted molecular imaging agents for cancer detection in the Sutcliffe laboratory and more specifically focus on improving the pharmacokinetics of peptide based molecular imaging agents. Molecular imaging agents under development in the Sutcliffe laboratory support pre-clinical studies in mice and non-human primates at the Center for Molecular and Genomic Imaging, as well as clinical studies through the UC Davis Comprehensive Cancer Center and the Department of Radiology. Dr Sutcliffe is the primary support Unit Director who will continue to work with Dr Hausner to plan, direct and monitor the proposed research.